We found that conjugation of the serotype 19F polysaccharide using reductive amination (as in 7vCRM) resulted in the formation of at least one additional epitope that is not present in the native form of the 19F polysaccharide or following 19F conjugation using a bifunctional spacer (as in the prototype vaccine 7vOMPC) or cyanylation (as in PHiD-CV). We also found that pneumococcal vaccines conjugated using cyanylation induce more opsonophagocytic antibodies against serotype 19F and a considerably higher level of cross-opsonophagocytic antibodies against serotype 19A than vaccines conjugated using reductive amination. In conclusion, these results suggest that the conjugation method can influence the functionality of the antibodies induced against the homologous serotype 19F and the cross-reactive serotype 19A of S. pneumoniae. 7vCRM (Prevenar/Prevnar; Pfizer, Inc.) contains capsular polysaccharides of Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, each conjugated to the nontoxic cross-reacting mutant diphtheria toxin CRM 197 . Serotype 19A was not included in 7vCRM, because it was expected that the immunological similarities with vaccine serotype 19F would elicit sufficient cross-protection, as observed for serotype 6B and the related serotype 6A (26, 38, 48, 52) . Serotypes 19F and 19A are indeed closely related biochemically (38, 52). Serotype 19A and 19F polysaccharides are composed of similar trisaccharide units polymerized through phosphate diester groups and differ only in the position of the linkage to the ␣-L-rhamnose residue: ␣(132) for 19F and ␣(133) for 19A (19, 29 
7vCRM (Prevenar/Prevnar; Pfizer, Inc.) contains capsular polysaccharides of Streptococcus pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F, each conjugated to the nontoxic cross-reacting mutant diphtheria toxin CRM 197 . Serotype 19A was not included in 7vCRM, because it was expected that the immunological similarities with vaccine serotype 19F would elicit sufficient cross-protection, as observed for serotype 6B and the related serotype 6A (26, 38, 48, 52) . Serotypes 19F and 19A are indeed closely related biochemically (38, 52) . Serotype 19A and 19F polysaccharides are composed of similar trisaccharide units polymerized through phosphate diester groups and differ only in the position of the linkage to the ␣-L-rhamnose residue: ␣(132) for 19F and ␣(133) for 19A (19, 29) .
Among the seven serotypes included in 7vCRM, the lowest protection against disease is observed for serotype 19F. For invasive pneumococcal disease due to serotype 19F, the reported effectiveness of 7vCRM ranges from 67% to 87% (4, 22, 48) , whereas for acute otitis media due to serotype 19F, the efficacy of 7vCRM is reported to be 25% (95% confidence interval [CI] , Ϫ14% to 51%) (11) . Despite this apparently weaker protection against serotype 19F than against the other serotypes, disease due to serotype 19F is well controlled by vaccination with 7vCRM. In contrast, a rise in the incidence of disease caused by the vaccine-related serotype 19A has been observed after the introduction of 7vCRM, especially in the United States, suggesting that 7vCRM provides no or limited cross-protection against serotype 19A (16, 32, 45) .
Following the successful introduction of 7vCRM in 2000, two additional pneumococcal conjugate vaccines (PCVs) were licensed on the basis of immunological noninferiority to 7vCRM: the pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV [Synflorix] ; GlaxoSmithKline [GSK] Biologicals) and 13vCRM (Prevnar 13; Pfizer, Inc.) (17, 49, 50) . PHiD-CV targets pneumococcal serotypes 1, 5, and 7F in addition to those targeted by 7vCRM (37, 46) . Eight of the 10 polysaccharides in PHiD-CV are conjugated to the nontypeable H. influenzae protein D, and the remaining 2 are conjugated to tetanus and diphtheria toxoids. As with 7vCRM, serotypes 6A and 19A were not included in PHiD-CV because the related serotypes 6B and 19F, which are included in PHiD-CV, were expected to provide cross-protection. 13vCRM contains serotypes 3, 6A, and 19A in addition to those targeted by PHiD-CV (5) .
Licensure based on immunological noninferiority requires serological assays that reflect clinical protection. However, the classically used enzyme-linked immunosorbent assays (ELISAs) determine the antibody concentrations but do not necessarily reflect the functional potential of the antibodies. Because opsonophagocytosis is the primary mechanism of protection against S. pneumoniae infections, the in vitro opsonoph-agocytosis activity (OPA) assay is acknowledged as the best surrogate for evaluating the protection provided by pneumococcal vaccines (18, 39, 47) .
Divergent estimates of vaccine efficacy could thus arise from these two assays. It was recently shown that although ELISA results indicate that 7vCRM induces antibodies against serotype 19F above threshold levels in a high proportion of children (99% [95% CI, 98% to 100%]), only 91% of children (95% CI, 88% to 94%) had functional antibodies (OPA titer, Ն8) against this serotype (37) . The latter estimate seems to correspond better with the observed effectiveness of 7vCRM in the United States (87% [95% CI, 65% to 95%]) (48) . Furthermore, serotype 19F required the highest antibody concentration to obtain 50% killing in the OPA assay (14) . For the vaccine-related serotype 19A, three doses of 7vCRM yielded only 2% (95% CI, 1% to 4%) of sera with OPA titers of Ն8 (37), the threshold considered to correlate with clinical effectiveness (14, 37, 50) . Similar results were found subsequently in other studies (20, 26) .
Because polysaccharides must be chemically modified before covalent linking to a carrier protein, the conjugation chemistry could alter the polysaccharide structure and, consequently, the exposure of epitopes. In 2002, Lee suggested that the conjugation method using reductive amination, in which pneumococcal polysaccharides are first oxidized by periodate to create aldehyde groups, modified the antigenic properties of some serotypes, including serotype 19F, from those of the native polysaccharides (25) .
Given the limited cross-protection against serotype 19A following the implementation of 7vCRM, we investigated the immune responses induced by PCVs containing serotype 19F conjugates but not serotype 19A in order to determine whether this low level of cross-protection is characteristic of the 19F polysaccharide (and therefore also applicable to PHiD-CV) or rather of the 19F-CRM conjugate used in 7vCRM (and therefore possibly different from the cross-protection provided by the 19F-diphtheria toxoid conjugate used in PHiD-CV). We thus compared the impact of different conjugation chemistries on the antipolysaccharide immune responses. To determine whether the conjugation method alters the polysaccharide structure and consequently the expression of epitopes, we used In studies A to F, the immunogenicity and safety of PHiD-CV were compared with those of 7vCRM. In study G, the immunogenicity, safety, and efficacy of the 11-valent prototype vaccine 11Pn-PD were analyzed in comparison to a control group receiving a hepatitis A vaccine. Detailed results with regard to the immunogenicity and safety of 11Pn-PD (33, 35, 36, 43) , PHiD-CV (2, 6, 46, 51) , and the coadministered vaccines (24) have been reported previously. All studies were conducted with healthy children between the ages of 6 and 16 weeks at the time of the first vaccine dose and between the ages of 11 and 18 months at the time of the booster dose.
Vaccines. The following vaccines were used: 7vCRM (Prevenar/Prevnar; Pfizer Inc., New York, NY); PHiD-CV (Synflorix; GSK Biologicals, Rixensart, Belgium); two PHiD-CV predecessor vaccine formulations, 4Pn-PD and 11Pn-PD (GSK Biologicals); a prototype vaccine conjugated to the outer membrane protein complex of Neisseria meningitidis serogroup B (7vOMPC; Merck & Co., Inc., Whitehouse Station, NJ); and the 23-valent nonconjugated polysaccharide vaccine (23vPS) (Pneumovax 23; Merck & Co., Inc.). 7vCRM contains capsular polysaccharides from seven pneumococcal serotypes (2 g each of the capsular polysaccharides for serotypes 4, 9V, 14, 18C, 19F, and 23F; 4 g of the capsular polysaccharide for serotype 6B) conjugated to the nontoxic diphtheria CRM 197 toxin. The polysaccharides in 7vCRM were activated by oxidation with sodium periodate, followed by linkage to the carrier protein by reductive amination (41) . PHiD-CV contains 1 g each of the capsular polysaccharides of S. pneumoniae serotypes 1, 5, 6B, 7F, 9V, 14, and 23F and 3 g of the serotype 4 capsular polysaccharide, each conjugated to a recombinant nonlipidated form of nontypeable H. influenzae protein D, along with 3 g of serotype 18C capsular polysaccharide conjugated to tetanus toxoid and 3 g of serotype 19F capsular polysaccharide conjugated to diphtheria toxoid. 4Pn-PD contains 1 g each of serotype 6B, 14, 19F, and 23F capsular polysaccharides (30) , and 11Pn-PD contains 1 g each of serotype 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, and 23F capsular polysaccharides, all conjugated individually to protein D. Conjugation for the PHiD-CV, 4Pn-PD, and 11Pn-PD vaccines was performed by cyanylation using 1-cyano-4-dimethylamino-pyridinium tetrafluoroborate (CDAP) (27) . 7vOMPC contains the following amounts of capsular polysaccharides: 1 g each for pneumococcal serotypes 4 and 14, 1.5 g for serotype 9V, 2 g each for serotypes 18C and 19F, 3 g for serotype 23F, and 5 g for serotype 6B. Each polysaccharide was individually conjugated to the outer membrane protein complex (OMPC) using a bigeneric spacer covalently linked by a multistep conjugation method (28) .
Sera. Serum samples from children vaccinated in studies A to G were collected and stored at Ϫ20°C until analysis at GSK Biologicals (Rixensart, Belgium). Selected sera from two other clinical studies were analyzed at the National Institute for Health and Welfare (THL, Helsinki, Finland): the Undeca-Pn-008 study, a phase II study that evaluated the immunogenicity and safety of the 11Pn-PD prototype vaccine in infants and toddlers (31) , and the Finnish Otitis Media vaccine efficacy trial, which compared in parallel a 7vCRM and a 7vOMPC vaccine group to a control hepatitis B vaccine group (8, 11, 21) .
Serum samples from adults were stored at Ϫ20°C and were analyzed at the Center for Biologics Evaluation and Research (CBER; U.S. Food and Drug Administration, Bethesda, MD). Sera from healthy, unimmunized adults were obtained from the National Institutes of Health blood bank (Bethesda, MD). Paired pre-and postvaccination sera from adults receiving 23vPS were kindly provided by David Goldblatt (Institute of Child Health, London, United Kingdom); paired sera from adults receiving 7vCRM were kindly provided by D. V. Madore (Wyeth Vaccines/Pfizer, Inc., Pearl River, NY) and M. H. Nahm (University of Alabama at Birmingham); and sera from adults receiving 7vOMPC were kindly provided by H. Ukwu (Merck & Co., Inc., Whitehouse Station, NJ). Finally, sera from adults receiving one dose of the 4Pn-PD or 11Pn-PD vaccine were also included in the analysis.
Antipneumococcal IgG ELISAs. For pediatric sera, antipneumococcal IgG concentrations were measured by ELISA with 22F preadsorption as previously described (15, 44) . The cutoff value for the 22F-ELISA used at GSK (see Fig. 3 ) was 0.05 g/ml IgG for all serotypes, which is an arbitrary value greater than the limit of quantitation of the assay for each of the serotypes. In this assay, an antibody concentration of 0.2 g/ml was shown to be equivalent to 0.35 g/ml by use of the reference ELISA (without 22F preadsorption) (15, 34) , which is the concentration recommended by the World Health Organization for noninferiority comparison of infant immune responses after primary immunization with a PCV (50) . For the ELISA used at the THL laboratory (44) (see Table 3 ), the limits for quantitation were 0.1 and 0.16 g/ml for serotypes 19A and 19F, respectively.
For adult sera, antipneumococcal IgG concentrations were measured at the CBER using an ELISA with 22F preadsorption as described previously (7) (see Fig. 1A and 2 ). Competitive inhibition ELISAs (see Fig. 1B and C) were performed at the CBER using 22F adsorption as described previously (7). The antigens used for coating microtiter plates in these experiments are described in Table 2 . For the native serotype 19F polysaccharide, plates were coated with a combination of 5 g/ml 19F polysaccharide and 5 g/ml methylated human serum albumin (HSA) to improve attachment. Only sera containing Ն2 g/ml of antibody to either the 19F polysaccharide or the 19F-HSA antigen were used for the inhibition experiments. The ratio of the concentration of IgG antibody against 19F-HSA to the concentration of IgG antibody against native 19F was calculated, and a ratio between 0.5 and 2 was considered as indicating no difference.
OPA assays. For pediatric sera, the OPA assay used by the GSK laboratory (see Fig. 3 ) was adapted from the method described by Romero-Steiner et al. (40) and was performed as described previously (14) . Similarly, the THL laboratory used a modification of the Romero-Steiner OPA assay (40) (see Table 3 ). The OPA titer was defined as the reciprocal of the lowest serum dilution that induced Ն50% bacterial killing relative to the levels in the control wells. For both OPA assays, the lowest serum dilution tested (assay cutoff) for all serotypes was 1:8, which corresponds to the titer that has been shown to correlate with protection against invasive pneumococcal disease (50).
Statistical analysis. The percentage of serum samples with an IgG antibody concentration of Ն0.2 g/ml according to GSK's 22F-ELISA and the percentage of serum samples with an OPA titer of Ն8 were computed with the 95% confidence interval (CI) on the according-to-protocol cohorts for immunogenicity.
The geometric mean antibody concentrations (GMCs) and the geometric mean OPA titers (GMTs) were calculated with the 95% CIs by taking the antilog of the mean of the log concentration/titer transformations. Reverse cumulative distribution curves of the antibody concentrations and OPA titers were plotted on the according-to-protocol cohorts for immunogenicity. Data were pooled across the three primary vaccination studies (studies A to C) and the three booster studies (studies D to F) for both 7vCRM and PHiD-CV vaccine recipients. The results for the 11Pn-PD group of study G were included in the graphs for comparison. Antibody concentrations and OPA titers below the assay cutoff were assigned an arbitrary value of half the assay cutoff (i.e., 0.025 g/ml for GSK's 22F-ELISA and 4 for GSK's OPA assay) for calculation of GMCs and GMTs, as well as for the reverse cumulative distribution curves.
RESULTS
Conjugation by reductive amination induces additional epitopes on the 19F polysaccharide. The ability of naturally occurring antibodies to bind the 19F polysaccharide was assessed at the CBER by measuring, in sera from unimmunized adults, the concentrations of antibodies to the native serotype 19F polysaccharide and to 19F-HSA, where the 19F polysaccharide is linked to human serum albumin by reductive amination. Approximately half (55/113 [48.7%]) of the sera had a 19F-HSA/native 19F IgG concentration ratio between 0.5 and 2, suggesting that they were equally reactive toward 19F-HSA and native 19F (Fig. 1A) . A large proportion of sera (44/ by periodate and linked to HSA by reductive amination expresses at least one additional epitope that is not present on either the native 19F polysaccharide or the 19F polysaccharide linked to tyramine by cyanylation. The 19F polysaccharide linked to CRM 197 using reductive amination (19F-CRM, obtained from the licensed 7vCRM vaccine) also strongly inhibited binding to 19F-HSA, suggesting that this putative additional epitope on 19F-HSA is also present on the 19F-CRM conjugate (Fig. 1C) . The distribution of the ratios of concentrations of IgG against 19F-HSA to the concentrations of IgG against native 19F, as measured using the CBER's 22F-ELISA, was then compared for sets of sera from adults who were either left unvaccinated or vaccinated with different pneumococcal vaccines (Fig. 2) . In adults vaccinated with 23vPS, the distribution of the ratios was relatively similar to that found for unvaccinated adults, with a large proportion of the ratios equal to or below 2. Most of the sera from adults vaccinated with 19F polysaccharides conjugated using cyanylation (4Pn-PD/11Pn-PD) or a bigeneric spacer (7vOMPC) bound equally to 19F-HSA and native 19F (ratios between 0.5 and 2), and only 6% to 10% of these sera had a 19F-HSA/native 19F antibody concentration ratio above 2. In contrast, the majority of samples (53%) from adults immunized with 7vCRM, produced using reductive amination, bound more to 19F-HSA (ratios, Ͼ2). These results suggest that antibodies against the additional epitope are induced mainly after vaccination with the 19F polysaccharide conjugated using reductive amination (as in 7vCRM), but not after vaccination with the native 19F polysaccharide (as in 23vPS) or the 19F polysaccharide conjugated using a bigeneric spacer (as in 7vOMPC) or cyanylation (as in PHiD-CV), where the levels of antibodies remain similar to those of naturally occurring antibodies to this additional epitope.
Finally, to determine whether other serotypes within pneumococcal serogroup 19 could be responsible for the antibodies recognizing the putative additional epitope, an inhibition ELISA was performed with polysaccharides from serotypes 19A, 19B, and 19C in sera from unimmunized adults (Fig. 1C) .
The level of inhibition of binding was similar to that obtained with 19F-tyra and native 19F polysaccharide. Thus, the heterologous serotypes 19A, 19B, and 19C were not the source of these naturally occurring antibodies.
Distribution of serotype 19F-and 19A-specific immune responses in vaccinated children. Reverse cumulative distribution curves of the antibody concentrations and the OPA titers (as measured by GSK's 22F-ELISA and OPA assays) after vaccination with PHiD-CV, 11Pn-PD, or 7vCRM are shown in Fig. 3 . Primary vaccination induced a strong antibody response against serotype 19F (Fig. 3A, left) . The distributions of antibody concentrations were in the same range for the three PCVs. The response was further improved following booster vaccination. However, the functionalities of these antibodies differed when they were measured by the OPA assay (Fig. 3A,  right) . The OPA GMT against serotype 19F obtained after primary vaccination with 7vCRM (52.4 [95% CI, 44.9 to 61.1]; pooled results from studies A to C) was lower than the OPA GMT obtained after primary vaccination with the prototype 11Pn-PD vaccine, which, in turn, was lower than that obtained after primary vaccination with PHiD-CV (308.6 [95% CI, 277.3 to 343.4]; pooled results from studies A to C). These differences were attenuated after the booster dose, although the OPA GMT after vaccination with PHiD-CV remained higher than those obtained after vaccination with the other two vaccines (835.3 [95% CI, 754.9 to 924.3] for PHiD-CV versus 346.0 [95% CI, 285.9 to 418.7] for 7vCRM).
The concentrations of antibodies and OPA titers against the related serotype 19A were lower than those against serotype 19F (Fig. 3B) . Following primary vaccination, PHiD-CV induced higher antibody concentrations against serotype 19A than 7vCRM or 11Pn-PD. Concentrations of antibodies against serotype 19A increased after the booster dose for all three vaccines. Although substantial amounts of anti-19A antibodies could be detected by ELISA after vaccination with all three PCVs, only a limited fraction of these antibodies were functional according to the OPA assay (Fig. 3B, right) . Only 1.8% (95% CI, 0.6% to 4.1%) of the children had functional antibodies against 19A after primary vaccination with 7vCRM, or from adults vaccinated with either 23vPS (n ϭ 24), 7vCRM (a vaccine conjugated using reductive amination [RA]) (n ϭ 15), 7vOMPC (a prototype vaccine conjugated using a bigeneric spacer [BS]) (n ϭ 33), or one of the two experimental vaccines 11Pn-PD and 4Pn-PD (both vaccines conjugated using cyanylation [CN]) (n ϭ 19). The 22F-ELISA was performed as described previously (7). To explore the impact of the conjugation method and the carrier protein on serotype 19F and 19A polysaccharide immunogenicity in children, we analyzed the quality of the antibodies against serotype 19F and the cross-reactive antibodies against serotype 19A induced after vaccination with three different PCVs (7vCRM, 7vOMPC, and 11Pn-PD). Serum samples from children who received three or four PCV doses were selected to represent similar anti-serotype 19F antibody concentrations in each vaccine group. The antibody concentrations ranged from 4.7 to 136.7 g/ml for serotype 19F and from less than 0.1 to 9.0 g/ml for serotype 19A. For serotype 19F, all of the samples tested from children vaccinated with 7vCRM or 11Pn-PD had OPA titers above the seropositivity cutoff (Ն8), as did 87% of the samples from children vaccinated with 7vOMPC (Table 3) . For serotype 19A, the rates of OPA seropositivity were 2 and 7 times higher in the 7vOMPC (20% [95% CI, 8% to 39%]) and 11Pn-PD (68% [95% CI, 47% to 85%]) groups, respectively, than in the 7vCRM group (10% [95% CI, 2% to 27%]). The 19A OPA GMTs were higher in the 11Pn-PD group (14.6 [95% CI, 9.0 to 24.1]) than in the two other groups (4.9 [95% CI, 3.8 to 6.3] for 7vCRM and 4.9 [95% CI, 4.2 to 5.8] for 7vOMPC). Thus, 7vCRM, 7vOMPC, and 11Pn-PD seem to have different abilities to induce functional cross-reactive antibodies against serotype 19A.
DISCUSSION
Our results showed that vaccination with 7vCRM or PHiD-CV induces high concentrations of antibodies against serotype 19F. However, higher levels of functional antibodies against 19F and 19A polysaccharides were induced by PHiD-CV, which uses cyanylation rather than reductive amination to conjugate polysaccharides to carrier proteins. One possible explanation is that conjugation of the 19F polysaccharide using reductive amination (as in 7vCRM) induced at least one additional epitope that is not present within the native form of the 19F polysaccharide or following 19F conjugation using cyanylation (as in PHiD-CV) or a bifunctional spacer (as in 7vOMPC).
The pneumococcal polysaccharides must be chemically activated before conjugation with the carrier protein. The periodate oxidation step prior to reductive amination breaks and opens the hexasaccharide ring structure (Fig. 4A) , which may lead to ring-opened conjugates, depending on the serotype. This could result in increased flexibility of the polysaccharide and therefore a change in epitope exposure. In addition, the ring-opened polysaccharides may then reclose after the reductive-amination process, allowing the polysaccharides to form additional new conformations, some of which may result in new epitopes. In contrast, cyanylation, which activates the hydroxyl residues without altering the ring structure, allows better preservation of the native polysaccharide epitopes (Fig. 4B) .
The periodate oxidation opens the hexasaccharide ring primary vaccination, the data from the PHiD-CV groups in studies A to C were pooled; the data from the 7vCRM groups in studies A to C were pooled; and the data from the POET study group (study G) were used for 11Pn-PD. For the booster vaccination, the data from the PHiD-CV groups in studies D to F were pooled; the data from the 7vCRM groups in studies D to F were pooled; and the data from the POET study group (study G) were used for 11Pn-PD. The dotted lines represent an assay cutoff of 0.05 g/ml for the 22F-ELISA and a titer of 8 for the OPA assay. The numbers of sera tested are given in parentheses in the keys. a Samples were obtained from children 1 month after the third or the fourth PCV dose, with a 2:1 ratio between the number of samples taken after three and four doses. GMC, geometric mean concentration; GMT, geometric mean titer.
b n, number of serum samples for which results were available.
VOL. 18, 2011 CONJUGATION OF PNEUMOCOCCAL 19F POLYSACCHARIDE 333 structures in most pneumococcal serotypes conjugated by this method, but the greatest effects are seen for serotypes 5, 18C, 19F, and 23F, because of the number of possible periodate activation sites on the polysaccharide (23) . Thus, additional epitopes are probably generated by reductive amination in serotypes other than 19F.
We found substantial levels of antibodies specific for this additional 19F epitope in some sera from unimmunized adults, indicating that the induced epitope is probably also present on other natural immunogenic materials. The heterologous group 19 polysaccharides (serotypes 19A, 19B, and 19C) were not the source of these naturally occurring antibodies. The antibodies specific for the putative additional epitope could thus be specific for an epitope found on a common commensal organism. This is analogous to the periodate-activated group B streptococcal type III polysaccharide, which shares a common epitope (not present in the native type III polysaccharide) with the pneumococcal type 14 polysaccharide (3).
The putative additional epitope generated by reductive animation induced antibodies with lower (or no) functionality against serotype 19F, as revealed by the OPA titer, than those induced by a cyanylation-conjugated or native polysaccharide (Table 3) . Differences in OPA titers may reflect variability not only in the quantity but also in the quality of the antibodies elicited by different conjugates. These results highlight the necessity of using OPA assays in addition to the reference ELISA recommended by WHO when one is evaluating immune responses induced by candidate PCVs (12, 50) .
Previous studies have suggested that antibodies against serotype 19F have lower functionality than antibodies against the other serotypes included in 7vCRM (9, 11, 14, 37) . Despite this apparently weaker protection against serotype 19F, invasive pneumococcal disease due to serotype 19F is well controlled by vaccination with 7vCRM. The functionality of the antibodies against serotype 19F induced after primary vaccination with the experimental 11Pn-PD vaccine was higher than that induced by 7vCRM. The efficacy of 11Pn-PD against acute otitis media caused by serotype 19F was demonstrated in the POET study (44.4% [95% CI, 8.3% to 66.3%]). To further improve the functionality of 19F-specific antibodies, alternative vaccine formulations were tested, and a diphtheria toxoid conjugate (19F-DT) was selected on the basis of improved OPA responses. PHiD-CV, which contains 19F-DT, demonstrated a better OPA response than 11Pn-PD and 7vCRM following primary vaccination, and also following the booster dose, when high OPA titers against 19F were obtained with all three PCVs (Fig. 3) .
Our results showed that although vaccination with 7vCRM induces high concentrations of antibodies that cross-react with serotype 19A polysaccharide, these cross-reactive antibodies have a low opsonophagocytic capacity, in contrast to antibodies induced by vaccination with PCVs prepared using cyanylation. Similar results were obtained by Yu et al. (52) . They showed that high antibody concentrations but low OPA titers were induced against serotype 19A after vaccination with two 5-valent prototype vaccines conjugated to CRM 197 using reductive amination, whereas, in contrast, low antibody concentrations but high OPA titers were induced after vaccination with 7vOMPC, conjugated using a bigeneric spacer. These results agree with the poor concordance between the level of serotype 19A-specific antibodies estimated by ELISA and their opsonophagocytic capacity, and they support the idea that both types of assay should be used to evaluate immune responses induced by new PCVs.
In the different studies that were carried out to assess the immunogenicity and safety of PHiD-CV (2, 46, 51), 20% to 30% of children had OPA titers of Ն8 against serotype 19A following a 3-dose primary vaccination with PHiD-CV, compared to less than 2% of children primed with 7vCRM. In addition, a booster dose in the second year of life resulted in serotype 19A OPA titers of Ն8 in 55% of PHiD-CV-immunized children and 27% of 7vCRM-immunized children (combined data set from this publication and references 46 and 51). FIG. 4 . Preparation of polysaccharide-protein conjugates using reductive amination or cyanylation. (A) Conjugation involves oxidation of the polysaccharide with sodium periodate to introduce reactive aldehydes, followed by linkage to the carrier protein using reductive amination. This method breaks and opens the hexasaccharide ring structure. After conjugation, a new immunogenic epitope can be produced due to the binding of new groups to the hexasaccharide ring. (B) Cyanylation using CDAP introduces a cyanate group to hydroxyl groups, which forms a covalent bond to the amino or hydrazide group upon addition of the protein component. After cyanylation conjugation, the hexasaccharide ring remains intact and other chemical groups are not able to bind.
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It should also be noted that some serum samples were tested at both the GSK and THL laboratories. When the serotype 19A OPA results from the two laboratories were compared, GSK's OPA assay had a false-negative rate of 23.5% compared to THL's multiplexed OPA assay (10), whereas for serotype 19F, there was 100% agreement between the two assays (data not shown). Thus, GSK's OPA assay may underestimate the functional responses against serotype 19A compared to THL's multiplexed OPA assay. Although an increase in the incidence of disease caused by serotype 19A has been observed since the introduction of 7vCRM, a recent analysis of the literature suggested that this vaccine could possibly provide some direct protection against serotype 19A disease in fully immunized children but that this modest effect might be masked by countervailing selection pressures, such as high antibiotic use (13) . The magnitude of clinical cross-protection against serotype 19A disease that can be provided with the cross-reactive immune responses induced by PHiD-CV remains unknown at present.
In conclusion, our results suggest that the conjugation method can influence the immunogenicity of the serotype 19F polysaccharide and the functionality of the antibodies induced against serotype 19F and the cross-reactive serotype 19A. Furthermore, our results suggest that both an IgG ELISA and an OPA assay should be used to evaluate and compare the immune responses induced by PCVs.
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